<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01395329</url>
  </required_header>
  <id_info>
    <org_study_id>BYS-MD-57</org_study_id>
    <nct_id>NCT01395329</nct_id>
  </id_info>
  <brief_title>Nebivolol and the Endothelin (ET)-1 System</brief_title>
  <acronym>NETS</acronym>
  <official_title>Nebivolol and the Endothelin (ET)-1 System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Boulder</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Boulder</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that nebivolol will reduce ET-1-mediated vasoconstrictor tone
      in adult humans with elevated blood pressure to a greater extent than either metoprolol or
      placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. The investigators hypothesize that nebivolol will reduce ET-1-mediated vasoconstrictor
           tone in adult humans with elevated blood pressure to a greater extent than either
           metoprolol or placebo.

        2. The investigators further hypothesize that reducing ET-1 vasoconstrictor activity
           contributes to the improvement in endothelial vasodilator function associated with
           nebivolol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>Systolic blood pressure was measured before the 12 week drug or placebo intervention and after the 12 week drug or placebo intervention.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>Diastolic blood pressure was measured before the 12 week drug or placebo intervention and after the 12 week drug or placebo intervention.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change in Forearm Blood Flow (FBF) Response to BQ-123 (100 Nmol/Min)</measure>
    <time_frame>Forearm blood flow was measured at 0-60 minutes before the 12 week drug or placebo intervention and 0-60 minutes after the 12 week drug or placebo intervention.</time_frame>
    <description>Forearm blood flow (FBF) was measured via strain-gauge venous occlusion plethysmography at rest and every 10 minutes thereafter for 60 minutes. The average percent change for before and after either drug or placebo was calculated as the FBF at (each time point-resting value)/resting value and multiplied by 100 to calculate the percent change. The baseline or resting value was measured before the start of each drug infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change in FBF Response to BQ-123 (100 Nmol/Min) + BQ-788 (50 Nmol/Min)</measure>
    <time_frame>Forearm blood flow was measured 0-120 minutes before the 12 week drug or placebo intervention and 0-120 minutes after the 12 week drug or placebo intervention.</time_frame>
    <description>Forearm blood flow (FBF) was measured via strain-gauge venous occlusion plethysmography at rest and every 10 minutes thereafter for 60 minutes. The average percent change for before and after either drug or placebo was calculated as the FBF at (each time point-resting value)/resting value and multiplied by 100 to calculate the percent change. The baseline or resting value was measured before the start of each drug infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FBF Response to Acetylcholine (ACh)</measure>
    <time_frame>Forearm blood flow was measured before the 12 week drug or placebo intervention and after the 12 week drug or placebo intervention.</time_frame>
    <description>FBF was measured via strain-gauge occlusion plethysmography at rest and in response to ACh (4.0, 8.0 and 16.0 ug/100 mL tissue/min) for 5 minutes at each dose. Flows during the last minute of rest and each drug dose were measured and the mean value reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FBF Response to Sodium Nitroprusside</measure>
    <time_frame>Forearm blood flow was measured before the 12 week drug or placebo intervention and after the 12 week drug or placebo intervention.</time_frame>
    <description>FBF was measured via strain-gauge occlusion plethysmography at rest and in response to sodium nitroprusside (1.0, 2.0 and 4.0 ug/100 mL tissue/min) for 5 minutes at each dose. Flows during the last minute of rest and each drug dose were measured and the mean value reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FBF Response to ACh in the Absence or Presence of Nonselective Endothelin A/B Blockade (BQ-123+BQ-788)</measure>
    <time_frame>Forearm blood flow was measured before the 12 week drug or placebo intervention and after the 12 week drug or placebo intervention.</time_frame>
    <description>FBF was measured via strain-gauge occlusion plethysmography at rest and in response to BQ-123+BQ-788 +ACh (4.0, 8.0 and 16.0 ug/100 mL tissue/min) for 5 minutes at each dose. Flows during the last minute of rest and each drug dose were measured and the mean value reported.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Prehypertension</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Systolic and Diastolic blood pressure will be measured before and after randomization to12 weeks of Nebivolol. Forearm blood flow will be measured in response to 100 nmol/min of BQ-123, BQ-123+BQ788 (50 mol/min), Acetylcholine (4.0, 8.0, 16.0 ug/100 mL tissue/min), Sodium Nitroprusside (1.0, 2.0, 4.0 ug/100 mL tissue/min) and BQ-123+BQ-788+Acetylcholine (same doses as above) will be measured before and after the 12 weeks of nebivolol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoprolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Systolic and Diastolic blood pressure will be measured before and after randomization to12 weeks of Metoprolol. Forearm blood flow will be measured in response to 100 nmol/min of BQ-123, BQ-123+BQ788 (50 mol/min), Acetylcholine (4.0, 8.0, 16.0 ug/100 mL tissue/min), Sodium Nitroprusside (1.0, 2.0, 4.0 ug/100 mL tissue/min) and BQ-123+BQ-788+Acetylcholine (same doses as above) will be measured before and after the 12 weeks of Metoprolol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Systolic and Diastolic blood pressure will be measured before and after randomization to12 weeks of placebo. Forearm blood flow will be measured in response to 100 nmol/min of BQ-123, BQ-123+BQ788 (50 mol/min), Acetylcholine (4.0, 8.0, 16.0 ug/100 mL tissue/min), Sodium Nitroprusside (1.0, 2.0, 4.0 ug/100 mL tissue/min) and BQ-123+BQ-788+Acetylcholine (same doses as above) will be measured before and after the 12 weeks of placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol</intervention_name>
    <description>5 mg tablet to be taken by mouth once per day for 12 weeks</description>
    <arm_group_label>Nebivolol</arm_group_label>
    <other_name>Bystolic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <description>100 mg tablet to be taken by mouth once per day for 12 weeks</description>
    <arm_group_label>Metoprolol</arm_group_label>
    <other_name>Toprol-XL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>gelatin capsule to be taken by mouth once per day for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min)</intervention_name>
    <description>The forearm blood flow response to the endothelin (ET) -1 A receptor blocker BQ-123 (100 nmol/min) for 60 minutes at baseline and at 12 weeks.</description>
    <arm_group_label>Metoprolol</arm_group_label>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>BQ-123</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min)</intervention_name>
    <description>The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.</description>
    <arm_group_label>Metoprolol</arm_group_label>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>BQ-123+BQ-788</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FBF response to Acetylcholine</intervention_name>
    <description>The FBF response to the endothelium-dependent vasodilator ACh (4, 8 and 16 ug/100 mL tissue/min) at baseline and at 12 weeks.</description>
    <arm_group_label>Metoprolol</arm_group_label>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>ACh</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FBF response to Sodium Nitroprusside</intervention_name>
    <description>The FBF response to the endothelium independent vasodilator NTP (1,2 and 4 ug/100 mL tissue/min) at baseline and at 12 weeks.</description>
    <arm_group_label>Metoprolol</arm_group_label>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>NTP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FBF response to BQ-123+BQ-788+ACh</intervention_name>
    <description>The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.</description>
    <arm_group_label>Metoprolol</arm_group_label>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>BQ-123+BQ-788+ACh</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be men and women of all races and ethnic backgrounds aged 45-65 years.

          -  Subjects will be prehypertensive/hypertensive defined as resting systolic blood
             pressure &gt;130 mmHg and &lt; 160 mm Hg and/or diastolic blood pressure &gt;80 mmHg and &lt; 100
             mm Hg.

          -  All of the women in the study will be postmenopausal (at least 1 year from last
             menstrual cycle) and not receiving hormone replacement therapy (HRT) currently or in
             the preceding 3-year period.

          -  Lastly, candidates will be sedentary as determined from the Stanford Physical Activity
             Questionnaire (&lt;35 kcal/wk) and will not have engaged in any program of regular
             physical activity for at least 1 year prior to the study.

        Exclusion Criteria:

          -  Candidates who smoke (currently or in the past 7 years), report more than low-risk
             alcohol consumption as defined as no more than 14 standard drinks/wk and no more than
             4 standard drinks/day for men and 7 standard drinks/wk and 3 standard drinks/day for
             women (a standard drink is defined as 12 ounces of beer, 5 ounces of wine, 1Â½ ounces
             of 80-proof distilled spirits)

          -  Potential candidates who are taking cardiovascular-acting (i.e. statins, blood
             pressure medication an aspirin) medications will not be eligible.

          -  Fasting plasma glucose &gt;126 mg/dL.

          -  Potential candidates with a resting heart rate of &lt; 50 beats/minute will be excluded.

          -  Use of hormone replacement therapy.

          -  In hypertensive subjects, a seated systolic blood pressure greater than 160 mmHg or a
             seated diastolic blood pressure greater than 100 mmHg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher A DeSouza, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado at Boulder</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC-Boulder Clinical and Translational Research Center</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>June 9, 2011</study_first_submitted>
  <study_first_submitted_qc>July 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2011</study_first_posted>
  <results_first_submitted>May 2, 2018</results_first_submitted>
  <results_first_submitted_qc>November 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 6, 2018</results_first_posted>
  <last_update_submitted>December 5, 2018</last_update_submitted>
  <last_update_submitted_qc>December 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Colorado, Boulder</investigator_affiliation>
    <investigator_full_name>Christopher DeSouza</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prehypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
    <mesh_term>Nitroprusside</mesh_term>
    <mesh_term>cyclo(Trp-Asp-Pro-Val-Leu)</mesh_term>
    <mesh_term>BQ 788</mesh_term>
    <mesh_term>Acetylcholine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nebivolol</title>
          <description>Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Metoprolol</title>
          <description>Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo: gelatin capsule to be taken by mouth once per day for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nebivolol</title>
          <description>Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Metoprolol</title>
          <description>Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo: gelatin capsule to be taken by mouth once per day for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="5.3"/>
                    <measurement group_id="B2" value="55" spread="4.1"/>
                    <measurement group_id="B3" value="56" spread="5.9"/>
                    <measurement group_id="B4" value="56" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Systolic Blood Pressure</title>
        <time_frame>Systolic blood pressure was measured before the 12 week drug or placebo intervention and after the 12 week drug or placebo intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Before Nebivolol</title>
            <description>Before randomization to Nebivolol</description>
          </group>
          <group group_id="O2">
            <title>After Nebivolol</title>
            <description>Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Before Metoprolol</title>
            <description>Before randomization to Metoprolol</description>
          </group>
          <group group_id="O4">
            <title>After Metoprolol</title>
            <description>Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Before Placebo</title>
            <description>Before randomization to placebo</description>
          </group>
          <group group_id="O6">
            <title>After Placebo</title>
            <description>Placebo: gelatin capsule to be taken by mouth once per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" spread="6.6"/>
                    <measurement group_id="O2" value="126" spread="7.8"/>
                    <measurement group_id="O3" value="140" spread="6.1"/>
                    <measurement group_id="O4" value="125" spread="9.3"/>
                    <measurement group_id="O5" value="139" spread="4.9"/>
                    <measurement group_id="O6" value="134" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diastolic Blood Pressure</title>
        <time_frame>Diastolic blood pressure was measured before the 12 week drug or placebo intervention and after the 12 week drug or placebo intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Before Nebivolol</title>
            <description>Before randomization to Nebivolol</description>
          </group>
          <group group_id="O2">
            <title>After Nebivolol</title>
            <description>Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Before Metoprolol</title>
            <description>Before randomization to Metoprolol</description>
          </group>
          <group group_id="O4">
            <title>After Metoprolol</title>
            <description>Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Before Placebo</title>
            <description>Before randomization to placebo</description>
          </group>
          <group group_id="O6">
            <title>After Placebo</title>
            <description>Placebo: gelatin capsule to be taken by mouth once per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" spread="5.2"/>
                    <measurement group_id="O2" value="77" spread="5.3"/>
                    <measurement group_id="O3" value="90" spread="7.6"/>
                    <measurement group_id="O4" value="77" spread="4.8"/>
                    <measurement group_id="O5" value="86" spread="7.7"/>
                    <measurement group_id="O6" value="83" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Forearm Blood Flow (FBF) Response to BQ-123 (100 Nmol/Min)</title>
        <description>Forearm blood flow (FBF) was measured via strain-gauge venous occlusion plethysmography at rest and every 10 minutes thereafter for 60 minutes. The average percent change for before and after either drug or placebo was calculated as the FBF at (each time point-resting value)/resting value and multiplied by 100 to calculate the percent change. The baseline or resting value was measured before the start of each drug infusion.</description>
        <time_frame>Forearm blood flow was measured at 0-60 minutes before the 12 week drug or placebo intervention and 0-60 minutes after the 12 week drug or placebo intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Before Nebivolol</title>
            <description>Before randomization to Nebivolol</description>
          </group>
          <group group_id="O2">
            <title>After Nebivolol</title>
            <description>Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Before Metoprolol</title>
            <description>Before randomization to Metoprolol</description>
          </group>
          <group group_id="O4">
            <title>After Metoprolol</title>
            <description>Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Before Placebo</title>
            <description>Before randomization to placebo</description>
          </group>
          <group group_id="O6">
            <title>After Placebo</title>
            <description>Placebo: gelatin capsule to be taken by mouth once per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Forearm Blood Flow (FBF) Response to BQ-123 (100 Nmol/Min)</title>
          <description>Forearm blood flow (FBF) was measured via strain-gauge venous occlusion plethysmography at rest and every 10 minutes thereafter for 60 minutes. The average percent change for before and after either drug or placebo was calculated as the FBF at (each time point-resting value)/resting value and multiplied by 100 to calculate the percent change. The baseline or resting value was measured before the start of each drug infusion.</description>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BQ-123 10 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="2.6"/>
                    <measurement group_id="O2" value="-1.0" spread="1.7"/>
                    <measurement group_id="O3" value="10.0" spread="3.7"/>
                    <measurement group_id="O4" value="11.1" spread="2.8"/>
                    <measurement group_id="O5" value="13.1" spread="4.6"/>
                    <measurement group_id="O6" value="15.7" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BQ-123 20 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" spread="3.3"/>
                    <measurement group_id="O2" value="6.0" spread="3.3"/>
                    <measurement group_id="O3" value="18.0" spread="4.7"/>
                    <measurement group_id="O4" value="18.7" spread="3.2"/>
                    <measurement group_id="O5" value="20.4" spread="3.1"/>
                    <measurement group_id="O6" value="14.7" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BQ-123 30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" spread="5.1"/>
                    <measurement group_id="O2" value="-1.1" spread="3.3"/>
                    <measurement group_id="O3" value="23.0" spread="4.6"/>
                    <measurement group_id="O4" value="21.1" spread="4.8"/>
                    <measurement group_id="O5" value="26.8" spread="5.1"/>
                    <measurement group_id="O6" value="23.3" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BQ-123 40 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" spread="6.3"/>
                    <measurement group_id="O2" value="3.8" spread="3.2"/>
                    <measurement group_id="O3" value="28.4" spread="4.9"/>
                    <measurement group_id="O4" value="28.9" spread="3.8"/>
                    <measurement group_id="O5" value="23.9" spread="4.3"/>
                    <measurement group_id="O6" value="25.7" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BQ-123 50 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8" spread="4.6"/>
                    <measurement group_id="O2" value="6.1" spread="3.6"/>
                    <measurement group_id="O3" value="31.4" spread="5.9"/>
                    <measurement group_id="O4" value="27.7" spread="4.8"/>
                    <measurement group_id="O5" value="29.0" spread="5.6"/>
                    <measurement group_id="O6" value="26.5" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BQ-123 60 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0" spread="6.4"/>
                    <measurement group_id="O2" value="1.1" spread="4.5"/>
                    <measurement group_id="O3" value="34.4" spread="5.7"/>
                    <measurement group_id="O4" value="30.6" spread="5.5"/>
                    <measurement group_id="O5" value="33.8" spread="5.3"/>
                    <measurement group_id="O6" value="30.4" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in FBF Response to BQ-123 (100 Nmol/Min) + BQ-788 (50 Nmol/Min)</title>
        <description>Forearm blood flow (FBF) was measured via strain-gauge venous occlusion plethysmography at rest and every 10 minutes thereafter for 60 minutes. The average percent change for before and after either drug or placebo was calculated as the FBF at (each time point-resting value)/resting value and multiplied by 100 to calculate the percent change. The baseline or resting value was measured before the start of each drug infusion.</description>
        <time_frame>Forearm blood flow was measured 0-120 minutes before the 12 week drug or placebo intervention and 0-120 minutes after the 12 week drug or placebo intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Before Nebivolol</title>
            <description>Before randomization to Nebivolol</description>
          </group>
          <group group_id="O2">
            <title>After Nebivolol</title>
            <description>Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Before Metoprolol</title>
            <description>Before randomization to Metoprolol</description>
          </group>
          <group group_id="O4">
            <title>After Metoprolol</title>
            <description>Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Before Placebo</title>
            <description>Before randomization to placebo</description>
          </group>
          <group group_id="O6">
            <title>After Placebo</title>
            <description>Placebo: gelatin capsule to be taken by mouth once per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in FBF Response to BQ-123 (100 Nmol/Min) + BQ-788 (50 Nmol/Min)</title>
          <description>Forearm blood flow (FBF) was measured via strain-gauge venous occlusion plethysmography at rest and every 10 minutes thereafter for 60 minutes. The average percent change for before and after either drug or placebo was calculated as the FBF at (each time point-resting value)/resting value and multiplied by 100 to calculate the percent change. The baseline or resting value was measured before the start of each drug infusion.</description>
          <units>Percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BQ-123 10 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="2.6"/>
                    <measurement group_id="O2" value="-1.0" spread="1.7"/>
                    <measurement group_id="O3" value="10.0" spread="3.7"/>
                    <measurement group_id="O4" value="11.1" spread="2.8"/>
                    <measurement group_id="O5" value="13.1" spread="4.6"/>
                    <measurement group_id="O6" value="15.7" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BQ-123 20 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" spread="3.3"/>
                    <measurement group_id="O2" value="6.0" spread="3.3"/>
                    <measurement group_id="O3" value="18.0" spread="4.7"/>
                    <measurement group_id="O4" value="18.7" spread="3.2"/>
                    <measurement group_id="O5" value="20.4" spread="3.1"/>
                    <measurement group_id="O6" value="14.7" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BQ-123 30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" spread="5.1"/>
                    <measurement group_id="O2" value="-1.1" spread="3.3"/>
                    <measurement group_id="O3" value="23.0" spread="4.6"/>
                    <measurement group_id="O4" value="21.1" spread="4.8"/>
                    <measurement group_id="O5" value="26.8" spread="5.1"/>
                    <measurement group_id="O6" value="23.3" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BQ-123 40 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" spread="6.3"/>
                    <measurement group_id="O2" value="3.8" spread="3.2"/>
                    <measurement group_id="O3" value="28.4" spread="4.9"/>
                    <measurement group_id="O4" value="28.9" spread="3.8"/>
                    <measurement group_id="O5" value="23.9" spread="4.3"/>
                    <measurement group_id="O6" value="25.7" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BQ-123 50 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8" spread="4.6"/>
                    <measurement group_id="O2" value="6.1" spread="3.6"/>
                    <measurement group_id="O3" value="31.4" spread="5.9"/>
                    <measurement group_id="O4" value="27.7" spread="4.8"/>
                    <measurement group_id="O5" value="29.0" spread="5.6"/>
                    <measurement group_id="O6" value="26.5" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BQ-123 60 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0" spread="6.4"/>
                    <measurement group_id="O2" value="1.1" spread="4.5"/>
                    <measurement group_id="O3" value="34.4" spread="5.7"/>
                    <measurement group_id="O4" value="30.6" spread="5.5"/>
                    <measurement group_id="O5" value="33.8" spread="5.3"/>
                    <measurement group_id="O6" value="30.4" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BQ-123+BQ-788 70 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0" spread="6.9"/>
                    <measurement group_id="O2" value="9.2" spread="3.7"/>
                    <measurement group_id="O3" value="33.2" spread="6.9"/>
                    <measurement group_id="O4" value="37.8" spread="5.7"/>
                    <measurement group_id="O5" value="37.5" spread="8.3"/>
                    <measurement group_id="O6" value="38.0" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BQ-123+BQ-788 80 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3" spread="7.0"/>
                    <measurement group_id="O2" value="16.1" spread="8.2"/>
                    <measurement group_id="O3" value="44.7" spread="7.3"/>
                    <measurement group_id="O4" value="32.2" spread="7.3"/>
                    <measurement group_id="O5" value="42.6" spread="9.5"/>
                    <measurement group_id="O6" value="45.0" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BQ-123+BQ-788 90 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.5" spread="7.1"/>
                    <measurement group_id="O2" value="21.8" spread="9.2"/>
                    <measurement group_id="O3" value="49.8" spread="9.5"/>
                    <measurement group_id="O4" value="47.4" spread="6.9"/>
                    <measurement group_id="O5" value="46.4" spread="8.9"/>
                    <measurement group_id="O6" value="47.1" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BQ-123+BQ-788 100 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" spread="7.8"/>
                    <measurement group_id="O2" value="22.3" spread="8.5"/>
                    <measurement group_id="O3" value="47.5" spread="7.4"/>
                    <measurement group_id="O4" value="42.0" spread="7.6"/>
                    <measurement group_id="O5" value="57.1" spread="9.5"/>
                    <measurement group_id="O6" value="53.4" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BQ-123+BQ-788 110 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" spread="8.5"/>
                    <measurement group_id="O2" value="18.9" spread="7.0"/>
                    <measurement group_id="O3" value="57.8" spread="10.4"/>
                    <measurement group_id="O4" value="48.1" spread="7.6"/>
                    <measurement group_id="O5" value="57.8" spread="7.8"/>
                    <measurement group_id="O6" value="52.8" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BQ-123+BQ-788 120 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.6" spread="9.0"/>
                    <measurement group_id="O2" value="20.4" spread="7.6"/>
                    <measurement group_id="O3" value="64.6" spread="9.8"/>
                    <measurement group_id="O4" value="55.4" spread="7.1"/>
                    <measurement group_id="O5" value="57.9" spread="9.5"/>
                    <measurement group_id="O6" value="49.5" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>FBF Response to Acetylcholine (ACh)</title>
        <description>FBF was measured via strain-gauge occlusion plethysmography at rest and in response to ACh (4.0, 8.0 and 16.0 ug/100 mL tissue/min) for 5 minutes at each dose. Flows during the last minute of rest and each drug dose were measured and the mean value reported.</description>
        <time_frame>Forearm blood flow was measured before the 12 week drug or placebo intervention and after the 12 week drug or placebo intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Before Nebivolol</title>
            <description>Before randomization to Nebivolol</description>
          </group>
          <group group_id="O2">
            <title>After Nebivolol</title>
            <description>Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Before Metoprolol</title>
            <description>Before randomization to Metoprolol</description>
          </group>
          <group group_id="O4">
            <title>After Metoprolol</title>
            <description>Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Before Placebo</title>
            <description>Before randomization to placebo</description>
          </group>
          <group group_id="O6">
            <title>After Placebo</title>
            <description>Placebo: gelatin capsule to be taken by mouth once per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>FBF Response to Acetylcholine (ACh)</title>
          <description>FBF was measured via strain-gauge occlusion plethysmography at rest and in response to ACh (4.0, 8.0 and 16.0 ug/100 mL tissue/min) for 5 minutes at each dose. Flows during the last minute of rest and each drug dose were measured and the mean value reported.</description>
          <units>mL/100 mL tissue/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="0.3"/>
                    <measurement group_id="O2" value="4.9" spread="0.4"/>
                    <measurement group_id="O3" value="5.3" spread="0.5"/>
                    <measurement group_id="O4" value="5.6" spread="0.5"/>
                    <measurement group_id="O5" value="4.8" spread="0.2"/>
                    <measurement group_id="O6" value="5.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACh 4.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" spread="0.8"/>
                    <measurement group_id="O2" value="13.9" spread="0.9"/>
                    <measurement group_id="O3" value="12.4" spread="1.0"/>
                    <measurement group_id="O4" value="12.0" spread="1.0"/>
                    <measurement group_id="O5" value="11.4" spread="0.6"/>
                    <measurement group_id="O6" value="13.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACh 8.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="0.8"/>
                    <measurement group_id="O2" value="15.0" spread="0.8"/>
                    <measurement group_id="O3" value="13.1" spread="1.1"/>
                    <measurement group_id="O4" value="13.2" spread="1.1"/>
                    <measurement group_id="O5" value="12.0" spread="0.6"/>
                    <measurement group_id="O6" value="13.7" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACh 16.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="0.8"/>
                    <measurement group_id="O2" value="16.4" spread="0.6"/>
                    <measurement group_id="O3" value="13.8" spread="1.1"/>
                    <measurement group_id="O4" value="14.1" spread="1.1"/>
                    <measurement group_id="O5" value="12.7" spread="0.8"/>
                    <measurement group_id="O6" value="13.9" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>FBF Response to Sodium Nitroprusside</title>
        <description>FBF was measured via strain-gauge occlusion plethysmography at rest and in response to sodium nitroprusside (1.0, 2.0 and 4.0 ug/100 mL tissue/min) for 5 minutes at each dose. Flows during the last minute of rest and each drug dose were measured and the mean value reported.</description>
        <time_frame>Forearm blood flow was measured before the 12 week drug or placebo intervention and after the 12 week drug or placebo intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Before Nebivolol</title>
            <description>Before randomization to Nebivolol</description>
          </group>
          <group group_id="O2">
            <title>After Nebivolol</title>
            <description>Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Before Metoprolol</title>
            <description>Before randomization to Metoprolol</description>
          </group>
          <group group_id="O4">
            <title>After Metoprolol</title>
            <description>Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Before Placebo</title>
            <description>Before randomization to placebo</description>
          </group>
          <group group_id="O6">
            <title>After Placebo</title>
            <description>Placebo: gelatin capsule to be taken by mouth once per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>FBF Response to Sodium Nitroprusside</title>
          <description>FBF was measured via strain-gauge occlusion plethysmography at rest and in response to sodium nitroprusside (1.0, 2.0 and 4.0 ug/100 mL tissue/min) for 5 minutes at each dose. Flows during the last minute of rest and each drug dose were measured and the mean value reported.</description>
          <units>mL/100 mL tissue/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="0.4"/>
                    <measurement group_id="O2" value="4.7" spread="0.3"/>
                    <measurement group_id="O3" value="4.9" spread="0.3"/>
                    <measurement group_id="O4" value="5.7" spread="0.5"/>
                    <measurement group_id="O5" value="5.2" spread="0.3"/>
                    <measurement group_id="O6" value="5.2" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium Nitroprusside 1.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="1.2"/>
                    <measurement group_id="O2" value="13.7" spread="1.0"/>
                    <measurement group_id="O3" value="14.1" spread="1.3"/>
                    <measurement group_id="O4" value="14.3" spread="1.2"/>
                    <measurement group_id="O5" value="12.8" spread="0.7"/>
                    <measurement group_id="O6" value="13.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium Nitroprusside 2.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" spread="1.3"/>
                    <measurement group_id="O2" value="15.2" spread="1.0"/>
                    <measurement group_id="O3" value="14.9" spread="1.3"/>
                    <measurement group_id="O4" value="15.1" spread="1.1"/>
                    <measurement group_id="O5" value="14.4" spread="0.8"/>
                    <measurement group_id="O6" value="15.3" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium Nitroprusside 4.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" spread="1.2"/>
                    <measurement group_id="O2" value="16.4" spread="1.1"/>
                    <measurement group_id="O3" value="15.8" spread="1.3"/>
                    <measurement group_id="O4" value="16.0" spread="1.0"/>
                    <measurement group_id="O5" value="15.8" spread="0.8"/>
                    <measurement group_id="O6" value="16.1" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>FBF Response to ACh in the Absence or Presence of Nonselective Endothelin A/B Blockade (BQ-123+BQ-788)</title>
        <description>FBF was measured via strain-gauge occlusion plethysmography at rest and in response to BQ-123+BQ-788 +ACh (4.0, 8.0 and 16.0 ug/100 mL tissue/min) for 5 minutes at each dose. Flows during the last minute of rest and each drug dose were measured and the mean value reported.</description>
        <time_frame>Forearm blood flow was measured before the 12 week drug or placebo intervention and after the 12 week drug or placebo intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Before Nebivolol</title>
            <description>Before randomization to Nebivolol</description>
          </group>
          <group group_id="O2">
            <title>After Nebivolol</title>
            <description>Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Before Metoprolol</title>
            <description>Before randomization to Metoprolol</description>
          </group>
          <group group_id="O4">
            <title>After Metoprolol</title>
            <description>Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Before Placebo</title>
            <description>Before randomization to placebo</description>
          </group>
          <group group_id="O6">
            <title>After Placebo</title>
            <description>Placebo: gelatin capsule to be taken by mouth once per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>FBF Response to ACh in the Absence or Presence of Nonselective Endothelin A/B Blockade (BQ-123+BQ-788)</title>
          <description>FBF was measured via strain-gauge occlusion plethysmography at rest and in response to BQ-123+BQ-788 +ACh (4.0, 8.0 and 16.0 ug/100 mL tissue/min) for 5 minutes at each dose. Flows during the last minute of rest and each drug dose were measured and the mean value reported.</description>
          <units>mL/100 mL tissue/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="0.3"/>
                    <measurement group_id="O2" value="4.7" spread="0.3"/>
                    <measurement group_id="O3" value="5.5" spread="0.4"/>
                    <measurement group_id="O4" value="6.0" spread="0.5"/>
                    <measurement group_id="O5" value="4.9" spread="0.2"/>
                    <measurement group_id="O6" value="5.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACh 4.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="0.8"/>
                    <measurement group_id="O2" value="13.8" spread="0.9"/>
                    <measurement group_id="O3" value="13.1" spread="1.1"/>
                    <measurement group_id="O4" value="12.4" spread="1.1"/>
                    <measurement group_id="O5" value="11.7" spread="0.6"/>
                    <measurement group_id="O6" value="13.3" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACh 8.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="0.7"/>
                    <measurement group_id="O2" value="15.0" spread="0.7"/>
                    <measurement group_id="O3" value="13.7" spread="1.2"/>
                    <measurement group_id="O4" value="13.7" spread="1.2"/>
                    <measurement group_id="O5" value="12.3" spread="0.7"/>
                    <measurement group_id="O6" value="13.7" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACh 16.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="0.7"/>
                    <measurement group_id="O2" value="16.1" spread="0.5"/>
                    <measurement group_id="O3" value="14.5" spread="1.2"/>
                    <measurement group_id="O4" value="14.7" spread="1.2"/>
                    <measurement group_id="O5" value="13.0" spread="0.8"/>
                    <measurement group_id="O6" value="13.9" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline+BQ123/788</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="0.5"/>
                    <measurement group_id="O2" value="5.8" spread="0.7"/>
                    <measurement group_id="O3" value="6.7" spread="0.4"/>
                    <measurement group_id="O4" value="7.4" spread="0.7"/>
                    <measurement group_id="O5" value="6.1" spread="0.4"/>
                    <measurement group_id="O6" value="5.6" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACh 4.0+BQ-123/788</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" spread="0.7"/>
                    <measurement group_id="O2" value="13.7" spread="0.9"/>
                    <measurement group_id="O3" value="16.1" spread="1.3"/>
                    <measurement group_id="O4" value="16.5" spread="1.3"/>
                    <measurement group_id="O5" value="13.5" spread="1.0"/>
                    <measurement group_id="O6" value="15.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACh 8.0+BQ-123/788</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" spread="0.7"/>
                    <measurement group_id="O2" value="14.5" spread="0.8"/>
                    <measurement group_id="O3" value="17.1" spread="1.2"/>
                    <measurement group_id="O4" value="17.6" spread="1.2"/>
                    <measurement group_id="O5" value="15.1" spread="0.9"/>
                    <measurement group_id="O6" value="16.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACh 16.0+BQ-123/788</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" spread="0.6"/>
                    <measurement group_id="O2" value="15.0" spread="0.7"/>
                    <measurement group_id="O3" value="17.9" spread="1.3"/>
                    <measurement group_id="O4" value="18.2" spread="1.2"/>
                    <measurement group_id="O5" value="16.2" spread="0.9"/>
                    <measurement group_id="O6" value="17.3" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nebivolol</title>
          <description>Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Metoprolol</title>
          <description>Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo: gelatin capsule to be taken by mouth once per day for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Christopher DeSouza</name_or_title>
      <organization>University of Colorado</organization>
      <phone>303-492-2988</phone>
      <email>desouzac@colorado.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

